title: Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes.
abstract: Insulin resistance (IR) and type 2 diabetes mellitus (T2DM) have been found to be associated with postprandial hypertriglyceridemia (PPHTg). However, whether PPHTg can cause IR and diabetes is not clear. We therefore investigated the role of PPHTg in development of T2DM in rat model of T2DM. 96 male Wistar rats were randomized into four groups (24 rats each). Control Group A, high sucrose diet (HSD) Group B, HSD+Pioglitazone (10 mg/kg/day) Group C and HSD+Atorvastatin (20 mg/kg/day) Group D. Fat and glucose tolerance tests were done at regular intervals in all groups besides insulin and body weight measurement. At 26 weeks, low dose streptozotocin (15 mg/kg, i.p.) was given to half of the rats. All rats were followed up till 48 weeks. PPHTg developed as early as week 2 in Group B and stabilized by week 14. Group B displayed highest PPHTg compared to other groups. Atorvastatin treatment (Group D) abolished PPHTg which became comparable to controls, pioglitazone treatment partially blunted PPHTg resulting in intermediate PPHTg. Group B with highest PPHTg showed highest subsequent IR, glucose intolerance (GI) and highest incidence of prediabetes at week 26 and diabetes at week 34 and 46 compared to other groups. Group D rats displayed lower IR, GI, low incidence of prediabetes and diabetes at these time points compared to Groups B and C. ROC analysis showed that triglyceride area under the curve of each time point significantly predicts the risk of diabetes. Present study provides the evidence that PPHTg predicts the development of IR, GI and T2DM in rat model of diet induced T2DM.
authors.affiliation: Center for Diabetes Endocrinology & Metabolism, Department of Medicine, University College of Medical Sciences (University of Delhi) & GTB Hospital, Delhi, India.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Aslam
authors.affiliation: Department of Pathology, University College of Medical Sciences (University of Delhi) & GTB Hospital, Delhi, India.
authors.forename: Sarla
authors.initials: S
authors.lastname: Aggarwal
authors.affiliation: Department of Pharmacology, University College of Medical Sciences (University of Delhi) & GTB Hospital, Delhi, India.
authors.forename: Krishna Kumar
authors.initials: KK
authors.lastname: Sharma
authors.affiliation: Department of Pharmacology, University College of Medical Sciences (University of Delhi) & GTB Hospital, Delhi, India.
authors.forename: Vikas
authors.initials: V
authors.lastname: Galav
authors.affiliation: Center for Diabetes Endocrinology & Metabolism, Department of Medicine, University College of Medical Sciences (University of Delhi) & GTB Hospital, Delhi, India.
authors.forename: Sri Venkata
authors.initials: SV
authors.lastname: Madhu
mesh_terms: D000818:Animals; D000069059:Atorvastatin / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D015984:Causality; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology* / Q000503:physiopathology; D004041:Dietary Fats / Q000633:toxicity*; D019422:Dietary Sucrose / Q000633:toxicity*; D018450:Disease Progression; D018149:Glucose Intolerance / Q000209:etiology* / Q000503:physiopathology; D005951:Glucose Tolerance Test; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D015228:Hypertriglyceridemia / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D050152:Intra-Abdominal Fat / Q000473:pathology; D008055:Lipids / Q000097:blood; D008099:Liver / Q000737:chemistry / Q000473:pathology; D008297:Male; D010179:Pancreas / Q000473:pathology; D000077205:Pioglitazone; D019518:Postprandial Period; D011236:Prediabetic State / Q000188:drug therapy / Q000503:physiopathology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D045162:Thiazolidinediones / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D004041:Dietary Fats; D019422:Dietary Sucrose; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D008055:Lipids; D045162:Thiazolidinediones; D000069059:Atorvastatin; D000077205:Pioglitazone